All News

Your daily dose of clinical news you may have missed.

New research offers insight into how women who use cannabis during pregnancy perceive the impacts of cannabis legalization.

Sustained weight loss with semaglutide 2.4 mg is a result of the drug's effects on control of eating, including reduced cravings and hunger and increased satiety, study authors write.

Your daily dose of clinical news you may have missed.

Bexagliflozin significantly improved glycemic control in adults when used as monotherapy, in combination with metformin, or when added to several SOC regimens.

Adults with T2D may be able to reduce their liver fat and improve their liver fibrosis stage with reductions in HbA1c, according to findings from a retrospective analysis.

Investigators report a 30% reduced risk of total joint replacement in persons with type 2 diabetes treated with metformin vs those who did not receive the drug.

Americans are putting off care, even for serious conditions, because of cost. Inflation may have driven the numbers to an all time high, a new survey suggests.

Your daily dose of clinical news you may have missed.

Australian investigators found a 14% higher risk of fracture for every 1-SD increment in level of HDL-C in community dwelling healthy adults aged ≥70 years.

Your daily dose of clinical news you may have missed.

This topline look at the KDIGO 2022 updated guideline highlights new recommendations for clinical use of SGLT2i, GLP-1 RA, and nonsteroidal MRA.

When counseling patients about weight gain prevention, limiting the frequency of larger meals is more beneficial than time-restricted eating, advised authors.

Ingestion of cannabis is now the cause of 1 in every 3 pediatric poisoning hospitalizations in Canadian provinces where edibles are sold legally.

Your daily dose of clinical news you may have missed.

After hospital discharge for heart failure, adults treated with either furosemide or torsemide had similar mortality rates, according to results from the TRANSFORM-HF clinical trial.

The mRNA vaccine returned efficacy of 83.7% against RSV-associated lower respiratory tract disease defined by ≥2 symptoms and of 82.4% against disease defined by ≥3 symptoms.

In women with osteoporosis treated with abolaparatide, trabecular bone score increased significantly, reflecting improved bone microarchitecture and strength.